New Study Shows Atrial Fibrillation Patients Treated with Warfarin Long-Term are at Increased Risk for Dementia

Presented at Heart Rhythm 2016, new study of more than 10,000 patients treated with warfarin long-term reveals higher rates of dementia for AF patients versus non-AF patients

May 05, 2016

Media Contact

Allison Kassel
BRG Communications
akassel@brgcommunications.com
703-739-8362
Shane Osborne
Heart Rhythm Society
media@hrsonline.org
202-464-3431

SAN FRANCISCO, May 5, 2016 – A new study has found an increased risk of dementia in patients with atrial fibrillation (AF) that receive long-term, blood thinner, warfarin (Coumadin) compared to patients that use warfarin for conditions other than AF. The study of more than 10,000 patients treated with warfarin long-term found that patients with AF experience higher rates of dementia, Alzheimer’s disease and vascular dementia compared to anticoagulated non-AF patients. The research was presented today at Heart Rhythm 2016, the Heart Rhythm Society’s 37th Annual Scientific Sessions.

AF is the most common sustained cardiac arrhythmia with incidence rates that are growing dramatically with population aging. Many other chronic disorders of aging, such as dementia, are also increasing. Dementia is a neurological disorder that impairs memory and other cognitive abilities, and it is now listed amongst the leading causes of morbidity and mortality in developed countries. AF can increase the risk of dementia because it exposes patients to both large and small clots that can affect brain function. Blood thinners used to prevent all forms of clots and strokes can increase the risk of both large and small brain bleeds that can also negatively impact brain function over time.

The study was conducted by the Intermountain Healthcare Clinical Pharmacist Anticoagulation Service, which is part of the Intermountain Healthcare system based in Salt Lake City. Researchers enrolled a total of 10,537 patients with no history of dementia prior to the study and who were treated with a blood thinner for AF and non-AF conditions like valvular heart disease and thromboembolism on a long-term basis. Other variables included age, hypertension, diabetes, hyperlipidemia, renal failure, smoking history, prior myocardial infarction or cerebral vascular accident, and heart failure. Participants were aged 18 years and older.

During a follow-up of approximately seven years, all types of dementia increased in the AF group more than the non-AF group. In both groups, however, the risk of dementia increased as the time in therapeutic range (TTR) decreased or became more erratic. When warfarin levels were consistently too high or too low, dementia rates increased regardless of why patients were receiving a blood thinner. However, regardless of the adequacy of anticoagulation, AF patients consistently experienced higher rates of all forms of dementia.

This finding indicates that the efficacy of therapy is strongly associated with dementia. Of note, researchers found that patients younger than 70 years tended to be the most susceptible to the risk of dementia.

“Our study results are the first to show that there are significant cognitive risk factors for patients treated with warfarin over a long period of time regardless of the indication for anticoagulation,” said lead author T. Jared Bunch, MD, director of heart rhythm research at Intermountain Medical Center Heart Institute and medical director for heart rhythm services for the Intermountain Healthcare system.

This study is important in many ways, Dr. Bunch said.

“First, as physicians we have to understand that although we need to use anticoagulants for many reasons including to prevent stroke in AF patients, at that same time there are risks that need to be considered some of which we are only right now beginning to understand. In this regard, only those that absolutely need blood thinners should be placed on them long-term,” he added. “Second, other medications like aspirin that may increase the blood thinners effect should be avoided unless there is a specific medical need. Finally, in people that are on warfarin in which the levels are erratic or difficult to control, switching to newer agents that are more predictable may lower risk.”

In further exploring the association between AF, anticoagulation and dementia, this study offers insight into future treatment for patients with AF and for those taking a blood thinner for other needs. With AF raising the risk of dementia in addition to and independent of anticoagulation, how the abnormal rhythm is treated may be a way to lower dementia risk.

Sessions details:

“Atrial Fibrillation Patients Treated with Long-term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared to Patients Receiving Warfarin Long-term for Other Indications” [Thursday, May 5, 2016, 9:30 a.m. – 10:30 a.m. PDT, EPicenter Theater 1, Hall D]

Heart Rhythm 2016 is the most comprehensive educational program for heart rhythm professionals, featuring more than 250 educational sessions and more than 130 exhibitors showcasing innovative products and services. The Heart Rhythm Society’s Annual Scientific Sessions have become the must-attend event of the year, allowing the exchange of new vital ideas and information among colleagues from every corner of the globe.

About the Heart Rhythm Society

The Heart Rhythm Society is the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education and optimal health care policies and standards. Incorporated in 1979 and based in Washington, DC, it has a membership of more than 5,900 heart rhythm professionals in more than 70 countries around the world. For more information, visit www.HRSonline.org .